Corporate strategies and tactics for more effective drug development.
November 1, 2011
The selection of clinical trial participants must meld with the changing demographics of America if industry is to improve medicines that work for patients.
 |
 | November 1, 2011
Industry critics point to a lag in NME approvals as proof of innovation stagnation, but combination products and new delivery systems are quietly saving lives, and bringing in big dollars.
|
September 1, 2011
By:William Looney
Pharm Exec talks to Dr. Mel Spigelman, President and CEO of the TB Alliance, about the organization's tuberculosis priorities.
|
September 1, 2011
By:Dr. Jill Conner
Industry and regulators alike must graple with the sensitivities associated with developing biosimilar drugs.
|
September 1, 2011
By:Richard Gilkich
Observational studies present a compelling real-world corollary to the classic randomized clinical trial.
|
 | September 1, 2011
Richard Barker, former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science.
|
July 1, 2011
By:William Looney
Pfizer's crizotinib development program combined organization, art, and science—and a large dose of unforeseen risk
|
July 1, 2011
By:Natalie Dickmeyer, Lindsay Rosenbeck
The objective is to make most cancers a curable, chronic condition. But with soaring costs, crowded therapeutic competition, and new diagnostic reimbursement challenges ahead, can industry deliver?
|
August 18, 2010
By:George Koroneos
In a huge blow to Eli Lilly's Alzheimer's pipeline, the drug giant was forced to end two clinical trials due to the fact that the treatment was actually making patients' memory recall worse.
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
